期刊论文详细信息
Diabetology & Metabolic Syndrome
Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials
Siu-wai Leung1  Zhimin Chen2  Yunzhen Shi2  Yang Guo2  Xiuqian Zhang2  Shuang Zhu2  Hongmei Zhu2 
[1] School of Informatics, University of Edinburgh, Edinburgh EH8 9AB, UK;State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China
关键词: Meta-analysis;    Type 2 diabetes mellitus;    Metformin;    Glimepiride;   
Others  :  812502
DOI  :  10.1186/1758-5996-5-70
 received in 2013-05-13, accepted in 2013-11-04,  发布年份 2013
PDF
【 摘 要 】

Background

Metformin treatment has been the most recommended monotherapy of type 2 diabetes mellitus (T2DM) for decades but is challenged by new antidiabetic drugs. This study conducted a meta-analysis of randomized controlled trials (RCT) comparing the efficacy of metformin and glimepiride in monotherapy of T2DM.

Methods

A literature search for RCTs on glimepiride and metformin was conducted on the bibliographic databases, including PubMed, Cochrane Library and ScienceDirect, from their inceptions to 25 Mar 2013. All RCTs were selected according to pre-specified eligibility criteria. The quality of articles was assessed with the Cochrane’s risk of bias tool. Statistical meta-analysis evaluated the overall effects and biochemical indices of T2DM. Sensitivity and subgroup analyses evaluated the robustness and explained the heterogeneity of the results. Begg and Egger’s tests quantified possible publication biases. Results were represented as "standard mean difference or odds ratio [95% confidence internals] P value".

Results

Fifteen RCTs with 1681 adult T2DM patients were included for meta-analysis. Metformin was not better than glimepiride in overall efficacy in controlling the levels of HbA1c, postprandial blood sugar (PPBS), fasting plasma insulin (FINS), systolic and diastolic blood pressures (SBP and DBP), and high density lipoprotein (HDL). Metformin was only more effective than glimepiride in controlling the levels of total cholesterol (TC, 0.33 [0.03, 0.63], P = 0.03), low-density lipoprotein (LDL, 0.35 [0.16, 0.53], P = 0.0002) and triglycerides (TG, 0.26 [0.05, 0.46], P = 0.01). Odds ratios of adverse events showed that glimepiride was more likely to induce hypoglycemia episodes and metformin was with a higher risk of gastrointestinal upset.

Conclusion

Metformin was not significantly better than glimepiride in glycemic control of T2DM, suggesting that glimepiride would be a good choice second to metformin in the monotherapy of T2DM.

【 授权许可】

   
2013 Zhu et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140709085313174.pdf 394KB PDF download
Figure 3. 38KB Image download
Figure 2. 59KB Image download
Figure 1. 61KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】
  • [1]The National Collaborating Centre for Chronic Conditions: Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: Royal College of Physicians; 2008.
  • [2]Association American Diabetes: Standards of medical care in diabetes-2013. Diabetes Care 2013, 36:S11-66.
  • [3]UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
  • [4]Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, on behalf of the UK Prosepective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
  • [5]Adler AI, Stratton IM, Haw N, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR, UK Prospective Diabetes Study Group: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
  • [6]Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemiain type 2 diabetes: a patient-centered approach. Diabetes Care 2012, 35:1364-1379.
  • [7]Saenz A, Fernandez-Esteban I, Mataix A, Ausejo Segura M, Roqué i Figuls M, Mohr D: Metformin monotherapy for type 2 diabetes mellitus. Cochrane DB Syst Rev 2009, 3:CD002966. doi:10.1002/14651858.CD002966.pub3
  • [8]Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW: 10-year follow-up of intensive glucose control in type 2 diabetes. NEJM 2008, 359:1577-1589.
  • [9]Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S: Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011, 154:602-614.
  • [10]Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, on behalf of the quarter study group: Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004, 89:6068-6076.
  • [11]Marre M, Gaal LV, Usadel KH, Ball M, Whatmough I, Guitard C: Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002, 4:177-186.
  • [12]Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW: Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2005, 27:1548-1561.
  • [13]Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV: Comparative outcomes study of metformin intervention versus conventional approach. Diabetes Care 2005, 28:539-543.
  • [14]Boussageon R, Suupper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C: Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLOS Med 2012, 9:e1001204.
  • [15]Rojas LBA, Gomes MB: Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013, 5:6-20. BioMed Central Full Text
  • [16]Hamaguchi T, Hirose T, Asakawa H, Itoh Y, Kamado K, Tokunaga K, Tomita K, Masuda H, Watanabe N, Namba M: Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide. Diabetes Res Clin Pract 2004, 66:S129-132.
  • [17]Rendell M: The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004, 64:1339-1358.
  • [18]Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM, for the PERISCOPE Investigators: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. JAMA 2008, 299:1561-1573.
  • [19]Schotborgh CE, Wilde AAM: Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Cardiovasc Res 1997, 34:73-80.
  • [20]Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T: Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med 2005, 22:980-985.
  • [21]Yoon KH, Shin JA, Kwon HS, Lee SH, Min KW, Ahn YB, Yoo SJ, Ahn KJ, Park SW, Lee KW, Sung YA, Park TS, Kim MS, Kim YK, Nam MS, Kim HS, Park IB, Park JS, Woo JT, Son HY: Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naive type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Diabetes Metab J 2011, 35:26-33.
  • [22]Rong W, Cai LS: Comparing the efficacy of glimepiride and metformin in patients who are secondary sulfonylurea failure. Chinese J Diabetes 2004, 12:211-212.
  • [23]Wang KL, Lei GD, Tang XX, Huang YH: Comparison of the efficacy of glimepiride and metformin in patients who are secondary sulfonylurea failure. Drug Research 2009., 18
  • [24]UK Prospective Diabetes Study. http://www.dtu.ox.ac.uk/ukpds_trial/index.php webcite
  • [25]HMR's Amaryl Launched For Diabetes In The USA. http://www.thepharmaletter.com/file/69437/hmrs-amaryl-launched-for-diabetes-in-the-usa.html webcite
  • [26]Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbol EL, Kober L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011, 32:1900-1908.
  • [27]Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS: Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metabol 2012, 14:803-809.
  • [28]Food and Drug Administration (FDA): Appoved drug products with therapeutic equivalence evaluations 32nd. U.S: Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, and Office of Generic Drugs; 2012.
  • [29]Higgins JPT, Green S (Eds): Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from http://www.cochrane-handbook.org webcite
  • [30]Review Manager (RevMan): [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2012.
  • [31]Viechtbauer W: Conducting meta-analyses in R with the metafor package. J Stat Software 2010, 36:1-48.
  • [32]The R Project for Statistical Computing. [ http://www.r-project.org/ webcite] Accessed in 2013-06-19
  • [33]Ling ZM: The clinical observation of glimepiride in treating type 2 diabetes. J Clin Med Pract 2003, 7:574-575.
  • [34]Ramachandran A, Snehalatha C, Salini J, Vijay V: Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes-a study in indians. J Assoc Physicians India 2004, 52:459-463.
  • [35]Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R: Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin. Dia Nutr Metab 2004, 17:143-150.
  • [36]González-Ortiz M, Martínez-Abundis E, Grupo para el Tratamiento de la Diabetes Mellitus con Combinaciones: Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy. Rev Inest Clin 2004, 56:327-333.
  • [37]Tang JZ, Mao JP, Yang ZF, Zhou ZG, Tang WP, Feng Q: Effects of glimepiride and metformin on free fatty acid in patients with type 2 diabetes mellitus. J Cent South Univ Technol 2004, 29:631-634.
  • [38]Ning J, Tang WL, Zhou ZG, Feng Q, Liu YH, Zhou WD: Effect of glimepiride and metformine on insulin resistance in type 2 diabetics. China J Mod Med 2006, 16:2224-2227.
  • [39]Wu PS: The clinical efficacy of glimepiride on previously untreated type 2 diabetes patients. Appl J Gen Pract 2007, 5:1084-1085.
  • [40]Xu ZQ, Yu JB: Clinical observation of glimepiride and metformin in newly diagnosed type 2 diabetes. Chin J Misdiagn 2007, 7:2454-2455.
  • [41]Li F, Tang GF, Tang TC, Yang YH, Zhang ZM: Glimepiride and metformin in the treatment of metabolism syndrome. J Bengbu Med Coll 2007, 32:445-446.
  • [42]Rahman IU, Malik SA, Bashir M, Khan RU, Idrees M: Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. British J Diabetes Vascular Med 2011, 11:137-140.
  • [43]Wang H: Observation of 68 cases of obese type 2 diabetes who are treated with metformin. Med Forum Mag 2011, 32:156-157.
  • [44]WHO expert consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363:157-163.
  • [45]Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
  • [46]Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
  • [47]Holstein A, Plaschke A, Egberts EH: Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001, 17:467-473.
  • [48]Sato J, Ohsawa I, Oshida Y, Fukuharu M, Hu XC, Tamagawa T, Sato Y: Comparison of the effects of three sulfonylureas on in vivo insulin action. Arzneimittel-Forsch 2001, 51:459-464.
  • [49]Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinmann B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
  • [50]Okayasu S, Kitaichi K, Hori A, Suwa T, Horikawa Y, Yamamoto M, Takeda J, Itoha Y: The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. Biol Pharm Bull 2012, 35:933-937.
  • [51]Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh S, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Nicholson WK, Block L, Odelola O, Dalal DS, Ogbeche GE, Chandrasekhar A, Hutfless S, Bass EB, Segal JB: Oral diabetes medications for adults with type 2 diabetes: an update. In Comparative Effectiveness Review No 27 (Prepared by Johns Hopkins University Evidence-based Practice Center under Contract No 290-02-0018) AHRQ Publication No. 11-EHC038-EF. Edited by Rockville MD. Agency for Healthcare Research and Quality; 2011. Available at: http://www.ncbi.nlm.nih.gov/books/NBK55754/ webcite
  • [52]Bugos C, Austin M, Atherton T, Viereck C: Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res Clin Pract 2000, 50:251-254.
  • [53]Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL: Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose–response trial. Am J Med 1997, 102:491-497.
  • [54]ClinicalTrials.gov http://clinicaltrials.gov/ct2/results?term=Diabetes+metformin+Glimepiride webcite
  文献评价指标  
  下载次数:18次 浏览次数:12次